2 income funds that have thrashed Neil Woodford

These two benchmark-thrashing equity income fund managers have given Neil Woodford a run for his money, says Harvey Jones.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Everybody loves star fund manager Neil Woodford, or rather they did. One year of underperformance and the doubters are out in force. CF Woodford Equity Income hasn’t done as badly as people claim, rising 13.1% in the past 12 months, but it still trailed its benchmark equity income index which grew 16.1%, and people don’t expect that. So should you shun the blue-eyed boy of equity income?

Stormy weather

Woodford has been through rough waters before, as you would expect with a manager who is happy to swim against the tide, and has always emerged with his reputation enhanced. I expect him to do it again, but it is always worth checking out the competition. Different fund managers have different styles and invest in different stocks, giving you much-needed diversification. The following two have outpaced Woodford over the last year, although they may not always do so.

Ben Whitmore’s £2.3bn Jupiter Income Trust is a minnow next to Woodford’s £10bn giant. But small is beautiful with the fund returning 23% in the past year, and 75% over five years. It has some crossover with the Woodford vehicle, both feature pharmaceutical stocks AstraZeneca and GlaxoSmithKline, although these two make up a whopping 16.48% of Woodford’s total fund, more than double Jupiter’s 7.7% exposure. Woodford has also gone massive on tobacco stocks, with a 14.21% total weighing in Imperial Brands and British American Tobacco, far greater than Jupiter.

Going global

These are Woodford’s hits. His misses include ignoring oil and commodity stocks, which enjoyed a bumper 2016, and going big on outsourcing company Capita Group, whose share price halved. He also shunned the banks while Whitmore has a 4.8% stake in HSBC Holdings, which leapt 50% in the last year.

Jupiter Income is 100% invested in the UK, Woodford Equity Income is around 14% exposure to other countries, notably the US, with smaller stakes in Norway, Ireland, Luxembourg and Switzerland. Robin Geffen’s Neptune Income has even greater US exposure at 20%, and its top 10 holdings feature no less than five US stocks: Microsoft Corporation, derivatives marketplace CME Group, JP Morgan Chase & Co, Wells Fargo & Co and Johnson Matthey.

Sector splits

Neptune Income therefore gives you greater diversification, with a completely different top 10 to Woodford. It also has has more energy exposure with a 3.34% stake in Royal Dutch Shell, and 3.26% in Rio Tinto. Geffen has returned 20% over the past year, and 55% over five years. 

Drilling down further, Woodford has 36.85% exposure to healthcare and 28.33% in financials, but has next to nothing in technology, consumer services, utilities or telecommunications. Jupiter Income has 25% in financials and 20% in consumer services, but then has a much more even spread of sectors. It is a similar story with Neptune, which has major financials exposure at 34%, followed by a broad spread across the sectors. You can see which man is making the big calls here: Woodford. Next year those calls might pay off.

Three-way bet

Finally, the income. Neptune is the high highest yielding of the three, returning 4.66% a year, beating Jupiter’s 3.5% and Woodford’s 3.17%. So a spread of all three funds may give you better balance than going all-in on Woodford.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones holds units in CF Woodford Equity Income but has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca, BP, HSBC Holdings, Imperial Brands, Rio Tinto, and Royal Dutch Shell B. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

2 recession-resistant UK stocks I’d buy and hold for a decade!

Our writer details two UK stocks she believes could still continue to perform well in a recession and not feel…

Read more »

Back view of blue NIO EP9 electric vehicle
Investing Articles

Down 31% this year! Is now the moment to buy NIO stock?

NIO stock has moved sharply downwards in the past couple of months. Christopher Ruane likes the business potential -- but…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

2 dividend stocks I reckon could grow payouts for years to come!

This Fool is looking for dividend stocks and explains why these two picks could be primed to grow their payouts…

Read more »

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

Should I buy, sell, or hold my Rolls-Royce shares at £3.50?

This Fool considers what he should do with his Rolls-Royce shares following the FTSE 100 company's excellent full-year results last…

Read more »

Couple working from home while daughter watches video on smartphone with headphones on
Investing Articles

With a spare £280, here’s how I’d start buying shares this March

Our writer reflects on what he has learnt on the stock market to explain how he would start buying shares…

Read more »

Businesswoman calculating finances in an office
Investing Articles

Are these expensive FTSE 100 stocks actually brilliant bargains?

Paul Summers takes a closer look at two FTSE 100 stocks that could recover strongly in time, despite already carrying…

Read more »

Investing Articles

What might the recent Aviva share price performance tell me as an investor?

Christopher Ruane looks at how the Aviva share price has performed over the past 12 months and considers whether he…

Read more »

Investing Articles

Down by a quarter, is the BT share price a steal?

The BT share price has more than halved in the past five years. What is holding it down -- and…

Read more »